Document is current

Any future updates will be listed below

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells

Crossref DOI link: https://doi.org/10.1136/rmdopen-2020-001306

Published Online: 2020-07-28

Published Print: 2020-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark